21/03/201721/10/2023 L-DOS47 Phase I Study Results to be Presented at the 9th International Conference of Contemporary Oncology admin 0 Comments
17/03/201726/01/2024 Helix Biopharma Corp. Announces Fiscal Second Quarter 2017 Results and Closing of Private Placement admin 0 Comments
27/02/201726/01/2024 Helix Biopharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody from the Government of Canada admin 0 Comments
22/02/201726/01/2024 30mil CAD$ Investment in European Centre of Cancer Immunotherapy admin 0 Comments
02/02/201726/01/2024 Helix Biopharma Corp. to Present at the BIO CEO & Investor Conference in New York admin 0 Comments
23/01/201726/01/2024 Helix Biopharma Corp. Announces CAR-T Poster Presentation at AARC Annual Meeting 2017 in Washington, D.C. admin 0 Comments
17/01/201726/01/2024 Helix Biopharma Corp. Announces Voting Results from its Annual and Special Meeting of Shareholders admin 0 Comments
30/12/201626/01/2024 Helix BioPharma Corps. Announces Additional Private Placement Closing admin 0 Comments